Targeting Clear Horizons: Finding the Path in Chronic Rhinosinusitis with Nasal Polyps

Target Audience
The educational design of this activity addresses the needs of ear, nose, and throat (ENT), allergy/clinical immunology, and pulmonology clinicians involved in the treatment of patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Statement of Need/Program Overview
The availability of effective, targeted therapies for CRSwNP is expanding and best practices for their use as well as placement within treatment algorithms is constantly evolving. This CME Circuit Training™ activity has been designed to flex your knowledge and build your clinical management muscles in CRSwNP. Utilizing a unique multimedia platform that consists of 4, 15-minute circuits, faculty will guide you through a series of workouts that will help strengthen your expertise and improve your care of patients with severe or uncontrolled CRSwNP.

Educational Objectives
After completing this activity, the participant should be better able to:
1. Describe clinically relevant elements of CRSwNP pathophysiology, focusing on implications for disease classification, comorbidity burdens, and treatment targets
2. Evaluate patients with CRSwNP for disease phenotypes, symptom control, and treatment responses
3. Discuss the mechanisms of action, clinical trial data, and prescribing parameters for biologic treatment options in CRSwNP
4. Tailor multimodal treatment regimens for patients with CRSwNP that reflect symptom burden, endotypes, comorbidities, and shared clinical decision-making

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score at least 75% on the posttest, and complete the program evaluation.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.

Disclosures of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Joseph K. Han, MD, FARS, FAAAAI, FAAOA: Consulting Fee: AstraZeneca plc, Genentech, Inc., GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi SA

Anju T. Peters, MD, MSCI: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis Pharmaceutical Corporation, OptiNose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA; Contracted Research: AstraZeneca plc, Merck & Co, Inc., OptiNose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA

The following planners and managers have no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirement
PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client " Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client " Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)